AG-1478 (Tyrphostin AG-1478)

For research use only.

Catalog No.S2728 Synonyms: NSC 693255

69 publications

AG-1478 (Tyrphostin AG-1478) Chemical Structure

CAS No. 153436-53-4

AG-1478 (Tyrphostin AG-1478, NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).

Selleck's AG-1478 (Tyrphostin AG-1478) has been cited by 69 publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description AG-1478 (Tyrphostin AG-1478, NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).
Targets
EGFR [1]
(Cell-free assay)
3 nM
In vitro

AG-1478 is high selective over ErbB2 and PDGFR with IC50 of >100 μM. [1] AG-1478 preferentially inhibits U87MG cells expressing truncated EGFR with IC50 of 8.7 μM, compared to those expressing endogenous wt EGFR or overexpressing exogenous wt EGFR with IC50 of 34.6 μM and 48.4 μM, respectively, and inhibits the DNA synthesis with IC50 of 4.6 μM, 19.67 μM, and 35.2 μM, respectively. AG-1478 also preferentially inhibits the tyrosine kinase activity and autophosphorylation of the ΔEGFR compared to endogenous or overexpressed exogenous wt EGFR. [2] AG-1478 (0.25 μM) abolishes the MAPK activation induced by Ang II, a Ca2+ ionophore as well as EGF but not by a phorbol ester or platelet-derived growth factor-BB in the VSMC. [3] AG-1478 inhibits EGF-induced mitogenesis of the BaF/ERX and LIM1215 cells with IC50 of 0.07 μM and 0.2 μM, respectively. [6] AG1478 is able to inhibit the function of ATP-binding cassette (ABC) transporters such as ABCB1 and ABCG2, with a more pronounced effect on ABCG2. [7]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
U87MG M4HTb2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1XYSJ4yODBizszN NF\rXlNFVVOR M1rRN2lEPTB;M{SuOkDPxE1? MlL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwQDd3MkG0OUc,QDd3MkG0OVww[T5?
U87MG.ΔEGFR M1jzNGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1jCdp4yODBizszN MUHEUXNQ M3rqU2lEPTB;OD63JO69VQ>? MmflQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwQDd3MkG0OUc,QDd3MkG0OVww[T5?
U87MG.wtEGFR. MXXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MXr+NVAxKM7:TR?= NGLlUnFFVVOR M2LQdGlEPTB;NEiuOEDPxE1? NV3NUYtGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOEe1NlE1PSd-OEe1NlE1PTxxYU6=
U87MG MnvFT4lv[XOnIHHzd4F6 M373S54yODBizszN NEXRT49FVVOR MWXpcohq[mm2czDFS2ZTKHS7cn;zbY5mKGurbnHz[UBi[3Srdnn0fS=> MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek85PzV{MUS1K|45PzV{MUS1QE9iRg>?
U87MG.ΔEGFR NFTmNGZMcW6jc3WgZZN{[Xl? MUP+NVAxKM7:TR?= NUP4R3l6TE2VTx?= NWW5Wmo1cW6qaXLpeJMhTUeIUjD0fZJwe2mwZTDrbY5ie2ViYXP0bZZqfHl? NGLCcoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi96N{WyNVQ2Lz56N{WyNVQ2RC:jPh?=
U87MG.wtEGFR. MojLT4lv[XOnIHHzd4F6 M3[2eJ4yODBizszN NV\GVmNDTE2VTx?= NI\MT5hqdmirYnn0d{BGT0[UIIT5do9{cW6nIHvpcoF{\SCjY4Tpeol1gQ>? NUf6[WU2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOEe1NlE1PSd-OEe1NlE1PTxxYU6=
HPV 16-immortalized human keratinocytes M4DE[2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVexWlVPhjVyIN88US=> Mk\kSG1UVw>? NWL1Zoh1cW6qaXLpeJMh[2WubDDndo94fGh? MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek86Ojh6N{iyK|46Ojh6N{iyQE9iRg>?
HPV 16-immortalized human keratinocytes NGS1N2VHfW6ldHnvckBie3OjeR?= Mo\mglUxKM7:TR?= M4rZbGROW09? NHn1SZNqdmS3Y3XzJIFzemW|dDDpckB1cGViQ3XscEBEgWOuZR?= M4PROlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzl{OEi3PFIoRjl{OEi3PFI9N2F-
HPV 16-immortalized human keratinocytes MYrBdI9xfG:|aYOgZZN{[Xl? NIf1WHR,PTBizszN MUXEUXNQ MYLpcoR2[2W|IHHwc5B1d3Orcz6= MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek86Ojh6N{iyK|46Ojh6N{iyQE9iRg>?
A431 MmPUT4lv[XOnIHHzd4F6 MYH+NVAh|ryP NXnQbHBwTE2VTx?= Mn32bY5pcWKrdIOgeIhmKGKjc3HsJIFv\CCWR1[t{tEue3SrbYXsZZRm\CC2eYLvd4lv\SCyaH;zdIhwenmuYYTpc44hd2ZidHjlJGVITlJ? M4TCb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyN{CyNlYzLz5zMEewNlI3OjxxYU6=
MDA-468  M33lZmtqdmG|ZTDhd5NigQ>? NWS4eWVKhjFyIN88US=> NHfn[pVFVVOR NHz6eXJqdmirYnn0d{B1cGViYnHzZYwh[W6mIGTHSk3PuS2|dHnteYxifGWmIIT5do9{cW6nIIDoc5NxcG:{eXzheIlwdiCxZjD0bIUhTUeIUh?= MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODdyMkK2Nkc,OTB5MEKyOlI9N2F-
A431 MlLnSpVv[3Srb36gZZN{[Xl? NXLXOVg4hjFyIN88US=> MkfXSG1UVw>? NXLm[pQ{cW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> NI\zVJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMEewNlI3Oid-MUC3NFIzPjJ:L3G+
MDA-MB-231 NXjSSW9wU2mwYYPlJIF{e2G7 NEPKepp,PSEQvF2= M{LVW2ROW09? NIHDOo5qdmirYnn0d{BGT0Zic4TpcZVt[XSnZDDwbI9{eGixconsZZRqd25ib3[gSmtJWg>? M{PG[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzMEOwNVQ3Lz5zMUCzNFE1PjxxYU6=
CNE2 NHzVc49Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M1Hne|ExOCEQvF2= MoD3SG1UVw>? M{HMZolvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBjgSB7OD60KS=> NYDIblBsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG0NVA{OjJpPkGxOFExOzJ{PD;hQi=>
CNE2 MY\LbY5ie2ViYYPzZZk> MYD+NVAxKM7:TR?= MVPEUXNQ MkL3bY5pcWKrdIOgSWdHWiC2eYLvd4lv\SCyaH;zdIhwenmuYYTpc44> NH7Qboo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUSxNFMzOid-MUG0NVA{OjJ:L3G+
CNE2 NYK1RXF2TnWwY4Tpc44h[XO|YYm= MnO1glExOCEQvF2= NEHXVINFVVOR M4e1dmlvcGmkaYTzJG1CWEtiYX7kJGFMXCCjY4TpeoF1cW:w M{XYOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzNEGwN|IzLz5zMUSxNFMzOjxxYU6=
CNE2 MmXwSpVv[3Srb36gZZN{[Xl? NWTBe2d2hjVyIN88US=> M2fCZWROW09? MVHh[oZm[3S|IHPlcIwh[3mlbHWg[Il{fHKrYoX0bY9v MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTRzMEOyNkc,OTF2MUCzNlI9N2F-
HSC-2 MmTFT4lv[XOnIHHzd4F6 NED5UXU5yqEQvF2= MoDaSG1UVw>? M3T5UIlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBGT0[UIHHu[EBCc3R? MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ6OUK4OUc,OTd4OEmyPFU9N2F-
HSC-2 NFO5VmxCeG:ydH;zbZMh[XO|YYm= NH\vTHA5yqEQvF2= MWTEUXNQ M3zMV4lvcGmkaYTzJGZiey2vZXTpZZRm\CCjcH;weI9{cXN? MmryQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4OEmyPFUoRjF5Nki5Nlg2RC:jPh?=
HEp-2 NXPNZVVCT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M3jxSJ4yOCEQvF2= NEPLcVBFVVOR NUL3UY02\W6qYX7j[ZMhd3KrZH;ubY4ucW6mdXPl[EBoem:5dHitbY5pcWKrdH;yfS=> M{DLclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMkCyO|QyLz5{MEKwNlc1OTxxYU6=
SubG1 NWC4cGszSXCxcITvd4l{KGG|c3H5 MXv+NVAh|ryP MkixSG1UVw>? MnXv[Y5p[W6lZYOgc5Jq\G:waX6tbY5lfWOnZDDhdI9xfG:|aYO= NUnWOJI3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCyNFI4PDFpPkKwNlAzPzRzPD;hQi=>
HEp-2 MUPGeY5kfGmxbjDhd5NigQ>? NY\SdGgyhjFyIN88US=> M2G1SWROW09? MWDlcohidmOnczDPdolld26rbj3pcoR2[2WmIFLhfEBi[3SrdnH0bY9vNCCEY3ytNkBl\We{YXTheIlwdiCjbnSgV2lTXDFiaX7hZ5RqfmG2aX;u NYDwUHhFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCyNFI4PDFpPkKwNlAzPzRzPD;hQi=>
H508 MVXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NVLtdIFyhjFizszN NHjWO5pFVVOR MVjtbZRq\2G2ZYOgR3BHNW2nZHnheIVlKEh3MEigZ4VtdCCpcn;3eIg> Ml\mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3MUS5NlQoRjJ4NUG0PVI1RC:jPh?=
A431 M17memFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M2TiOHRme3SnZDDmc5Ih[W62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzMEBKSzVyPUKw{txO NVrsVllRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUWxNFk3PDJpPkG1NVA6PjR{PD;hQi=>
HeLa NWmwU|ZFTnWwY4Tpc44h[XO|YYm= NX;MOIVoOzBibXnudy=> NYq4bWVEUW6qaXLpeIlwdiCxZjDFS2ZTKGG3dH;wbI9{eGixconsZZRqd25iaX6gbJVu[W5iSHXMZUBk\WyuczDwdoVqdmO3YnH0[YQh\m:{IEOwJI1qdnNicILpc5IhfG9iRVfGJJN1cW23bHH0bY9vKGK7IGfld5Rmem5iYnzveJRqdmd? MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTdzOECyPUc,OjF5MUiwNlk9N2F-
BT-37 NHjxfm9yUFSVIHHzd4F6 MXLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-SH MYHxTHRUKGG|c3H5 MoXadWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB1643 NGK2TZJyUFSVIHHzd4F6 NG\Xd3hyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz M4HFfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50 MVjxTHRUKGG|c3H5 M3zuVZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO= NWXQRnpRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
HEK293 NGTNO4lHfW6ldHnvckBie3OjeR?= M1vtUVEhcHJ? MnfLTY5pcWKrdHnvckBw\iCqdX3hckBnfWyuIHzlcod1cCCSS13ZWFEh\XiycnXzd4VlKGmwIFjFT|I6OyClZXzsd{B2e2mwZzDFSnMhMDJ2NzD0c{AzPTlicnXzbYR2\XNrIHHzJJN2[nO2cnH0[UBi\nSncjCxJIhzKGK7IH\seY9z\XOlZX7j[UBxd2yjcnn6ZZRqd25iaX3teY5w[XOjeTygT4k:OS56N988US=> NXnIeXBvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm5OFEyQTNpPkK5PVQyOTl|PD;hQi=>
HEK293 MmnrSpVv[3Srb36gZZN{[Xl? NEKyR|kyKGi{ MYLJcohq[mm2aX;uJI9nKGi3bXHuJIZ2dGxibHXu[5RpKFCNTWnUNUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJJV{cW6pIFXGV{ApOjR5IITvJFI2QSC{ZYPp[JVmeyliYYOgd5Vje3S{YYTlJIFnfGW{IEGgbJIh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiCrbX31co9ie2G7LDDJR|UxRTF7LkdOwG0> M1zWPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OUSxNVk{Lz5{OUm0NVE6OzxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
EGFR / Neu / p-Tyr ; 

PubMed: 10931950     


MCF-10AyTE cells with or without AG-1478. After 24 h, cell lysates were prepared in EBC buffer and subjected to immunoblot procedures for EGFR, ErbB-2yNeu, and P-Tyr. Levels of a 180-kDa P-Tyr band, probably representing EGFR and ErbB-2yNeu, were reduced by AG-1478 without any change in receptor protein content.

Shc / PLC-γ1 ; 

PubMed: 10931950     


MCF-10AyTE cells with or without AG-1478. After 24 h, cell lysates were prepared in EBC buffer and subjected to immunoblot procedures for EGFR, ErbB-2yNeu, and P-Tyr. Levels of a 180-kDa P-Tyr band, probably representing EGFR and ErbB-2yNeu, were reduced by AG-1478 without any change in receptor protein content.

10931950
Growth inhibition assay
Cell viability ; 

PubMed: 25258648     


Dose-dependent effects of EGFR inhibitor AG-1478 on EGF-induced cell viability in OVCAR-3 cells. Cells were treated for 48 h with EGF (10 ng/mL) alone or in combination of AG-1478 (0, 0.25, 0.5 and 1 µmol/L). A cell viability assay was performed using MTT and values were normalized to untreated controls (no EGF, no inhibitors). Blackened bars were EGF treated. *, ** indicate a significant increase (p≤0.05) and # indicates a significant decrease (p≤0.05) between groups by ANOVA and Tukey’s pairwise comparisons. Experiments were performed in triplicate and all data are shown as mean ± SEM.

25258648
In vivo Administration of AG-1478 blocks phosphorylation of the EGFR at the tumor site and inhibits the growth of A431 xenografts that overexpress the WT EGFR and glioma xenografts expressing the de2-7 EGFR. Even subtherapeutic doses of AG-1478 significantly enhance the efficacy of cytotoxic drugs, with the combination of AG-1478 and temozolomide displaying synergistic antitumor activity against human glioma xenografts. The combination of AG-1478 and an anti-EGFR antibody (mAb 806) displays additive and in some cases synergistic, antitumor activity against tumor xenografts overexpressing the EGFR. [4] The combination of AG-1478 (0.4 mg) with a single dose of 25 μCi 90Y-CHX-A''-DTPA-hu3S193 results in a significant enhancement of efficacy compared with either agent alone. [5]

Protocol

Cell Research:

[2]

- Collapse
  • Cell lines: U87MG
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to different concentrations of AG-1478 for 72 hours in 96-well plates. The effects of AG-1478 on cell growth are examined using an Alamar Blue assay. A 20-μL aliquot of Alamar Blue is added to each well, and its absorbance is determined using a Spectromax Scanning Micro plate Reader. The effects of AG-1478 are expressed as percentage of growth inhibition using untreated cells as the control (0% inhibition). Cellular DNA synthesis is determined using a [3H]thymidine incorporation assay.


    (Only for Reference)
Animal Research:

[4]

- Collapse
  • Animal Models: Female BALB/c nu/nu mice inoculated s.c. with A431 or U87MG.Δ2-7 tumor cells
  • Dosages: ~1 mg/kg
  • Administration: Injection i.p. three times per week
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 25 mg/mL (79.17 mM)
Water Insoluble
Ethanol ''13 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 315.75
Formula

C16H14ClN3O2

CAS No. 153436-53-4
Storage powder
in solvent
Synonyms NSC 693255
Smiles COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Cl)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Related EGFR Products

Tags: buy AG-1478 (Tyrphostin AG-1478) | AG-1478 (Tyrphostin AG-1478) supplier | purchase AG-1478 (Tyrphostin AG-1478) | AG-1478 (Tyrphostin AG-1478) cost | AG-1478 (Tyrphostin AG-1478) manufacturer | order AG-1478 (Tyrphostin AG-1478) | AG-1478 (Tyrphostin AG-1478) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID